MediWound Ltd. (MDWD)
NASDAQ: MDWD · Real-Time Price · USD
16.63
+0.05 (0.30%)
May 26, 2026, 2:01 PM EDT - Market open
MediWound Revenue
In the year 2025, MediWound had annual revenue of $16.96M, down -16.14%. MediWound had revenue of $1.87M in the quarter ending December 31, 2025, a decrease of -68.03%.
Revenue (ttm)
$16.96M
Revenue Growth
-16.14%
P/S Ratio
12.63
Revenue / Employee
$140,157
Employees
121
Market Cap
213.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.96M | -3.26M | -16.14% |
| Dec 31, 2024 | 20.22M | 1.54M | 8.22% |
| Dec 31, 2023 | 18.69M | -7.81M | -29.48% |
| Dec 31, 2022 | 26.50M | 2.73M | 11.50% |
| Dec 31, 2021 | 23.76M | 2.00M | 9.19% |
| Dec 31, 2020 | 21.76M | -10.03M | -31.54% |
| Dec 31, 2019 | 31.79M | 28.39M | 834.70% |
| Dec 31, 2018 | 3.40M | 905.00K | 36.26% |
| Dec 31, 2017 | 2.50M | 938.00K | 60.21% |
| Dec 31, 2016 | 1.56M | 957.00K | 159.23% |
| Dec 31, 2015 | 601.00K | 342.00K | 132.05% |
| Dec 31, 2014 | 259.00K | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 78.09M |
| Atrium Therapeutics | 36.68M |
| Keros Therapeutics | 33.18M |
| Tonix Pharmaceuticals Holding | 17.56M |
| Caribou Biosciences | 11.20M |
| Whitehawk Therapeutics | 7.15M |
MDWD News
- 19 days ago - MediWound to Report First Quarter 2026 Financial Results - GlobeNewsWire
- 6 weeks ago - Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement - GlobeNewsWire
- 7 weeks ago - MediWound to Present New EscharEx® Data at Leading Wound Care Conferences - GlobeNewsWire
- 7 weeks ago - MediWound says Vericel awarded ten-year contract valued at up to $197M - TheFly
- 7 weeks ago - MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million - GlobeNewsWire
- 2 months ago - MediWound management to meet with Maxim - TheFly
- 2 months ago - MediWound Files Annual Report on Form 20-F - GlobeNewsWire
- 2 months ago - MediWound Earnings Call Transcript: Q4 2025 - Transcripts